Kathleen K Harnden (Kathleen Harnden)
Publication Activity (10 Years)
Years Active: 2022-2024
Publications (10 Years): 2
Publications (10 Years): 2
Publications
- Komal L Jhaveri, Elgene Lim, Rinath M Jeselsohn, Cynthia X Ma, Erika Paige Hamilton, Cynthia Osborne, Manali Bhave, Peter A Kaufman, J Thaddeus Beck, Luis Manso Sanchez, Ritesh Parajuli, Hwei-Chung Wang, Jessica J Tao, Seock-Ah Im, Kathleen K Harnden, Kan Yonemori, Ajay Dhakal, Patrick Neven, Philippe Aftimos, Jean-Yves Pierga, Yen-Shen Lu, Timothy Larson, Yolanda Jerez, Kostandinos Sideras, Joo Hyuk Sohn, Sung-Bae Kim, Cristina Saura, Aditya Bardia, Sarah L Sammons, Francesca Bacchion, Yujia Li, Eunice Yuen, Shawn T Estrem, Vanessa Rodrik-Outmezguine, Bastien Nguyen, Roohi Ismail-Khan, Lillian M Smyth, Muralidhar BeeramImlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
- Francois-Clement Bidard, Virginia G Kaklamani, Patrick Neven, Guillermo Streich, Alberto J Montero, Frédéric Forget, Marie-Ange Mouret-Reynier, Joo Hyuk Sohn, Donatienne Taylor, Kathleen K Harnden, Hung T Khong, Judit Kocsis, Florence Dalenc, Patrick M Dillon, Sunil Babu, Simon H Waters, Ines Deleu, José A García Sáenz, Emilio Bria, Marina Elena Cazzaniga, Janice Lu, Philippe Aftimos, Javier Cortes, Shubin Liu, Giulia Tonini, Dirk Laurent, Nassir Habboubi, Maureen G Conlan, Aditya BardiaElacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 40 (28) (2022)